Zenas BioPharma Celebrates Major Milestones in Q3 2025
- Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end.
- Reported highly positive 12-week primary endpoint results from Phase 2 MoonStone trial of obexelimab in Relapsing MS (RMS).
- Secured development and commercialization rights for three autoimmune product candidates, including orelabrutinib, a BTK Inhibitor in Phase 3 for progressive MS.
- Entered an obexelimab funding agreement with Royalty Pharma for up to $300 million, including a $75 million upfront payment.
Zenas BioPharma, Inc. (NASDAQ: ZBIO), a leading clinical-stage biopharmaceutical company focused on autoimmune disease treatments, recently shared its financial results for the third quarter and provided updates on its corporate achievements. The Company is passionate about developing transformative therapies for patients struggling with autoimmune diseases, including those affected by Multiple Sclerosis.
CEO Lonnie Moulder stated, "The outstanding results from our Phase 2 MoonStone trial for obexelimab in relapsing multiple sclerosis reaffirm its substantial impact in targeting the pathogenic role of B cells in autoimmune conditions. Moreover, our expansion into licensing three promising product candidates highlights our commitment to innovation in this field."
Obexelimab's Pivotal Phase 3 Data
Anticipated topline results from the Phase 3 INDIGO trial, designed to assess the efficacy and safety of obexelimab in IgG4-RD, will be released at year-end. This trial is notable for being the largest clinical study conducted on this patient population to date, aiming to provide comprehensive insights into the drug's performance.
Exciting Developments in Relapsing MS
Zenas recently shared impressive results from the Phase 2 MoonStone trial of obexelimab, which met its primary endpoint with a statistically significant 95% relative reduction in new lesions. This reinforces the safety profile of obexelimab as well, with adverse events being typically mild and manageable. Zenas plans to release data from the 24-week follow-up of this trial in the upcoming months, further clarifying the drug's clinical potential.
Strengthening the Product Pipeline
Zenas has made notable strides by entering into a license agreement with InnoCare Pharma, giving them global rights to orelabrutinib—a potential franchise for treating progressive forms of MS. This move positions the company to not only take a significant role in managing this condition but also to explore other promising therapeutic areas through their newly added pipeline candidates.
Funding and Financial Strength
In a strategic financial decision, Zenas secured a significant private placement that raised $120 million, affirming investor confidence amid their operational expansions. With cash and equivalents totaling over $300 million as of the quarter's end, the company is well-positioned to support ongoing clinical trials and operational needs into late 2026. Management anticipates that the independent $75 million milestone payments from Royalty Pharma will extend this financial runway well into 2027.
Other Pipeline Updates
Ongoing clinical trials are evolving, covering multiple pathways in autoimmune disease treatment. The Company continues to enroll patients in the Phase 2 SunStone trial for SLE and is preparing for the initiation of Phase 3 trials for orelabrutinib focusing on Primary and Secondary Progressive MS, set to commence in early 2026.
Frequent Updates and Future Expectations
The Zenas team is committed to overcoming the challenges presented in autoimmune disorder therapeutics, leveraging their innovative drugs to provide patients with new hope. Their research advancements are a testament to their resilience and vision for a future where better treatments for autoimmune diseases are not just a goal but a reality.
For more information about Zenas BioPharma, please reach out through their media contact, Argot Partners, at Zenas@argotpartners.com.
Frequently Asked Questions
What is Zenas BioPharma's focus?
Zenas BioPharma is dedicated to developing transformative therapies for autoimmune diseases.
What are the key products in Zenas BioPharma's pipeline?
Key products include obexelimab and orelabrutinib, aimed at treating various forms of Multiple Sclerosis.
What recent financial achievements has Zenas made?
Zenas raised $120 million from a private placement and secured a funding agreement worth up to $300 million.
Where can I find more information on Zenas BioPharma?
Visit their official website at zenasbio.com for the latest updates.
When can we expect results from the Phase 3 INDIGO trial?
Topline results from the INDIGO trial are expected to be announced at the end of the year.
